Position in XERS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$115,042,262
+$39,956,714 QoQ
Shares Held
14,525,539
+12.2% QoQ
Ownership
7.97%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 238 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $21,635,633,053 across 65 Drug Manufacturers - Specialty & Generic names. XERS ranks #24 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
5,294,529 | $2,868,734,637 | |
| 2 | ZTS |
Zoetis Inc.
|
39,430,181 | $2,833,452,797 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
13,711,607 | $2,310,954,234 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
63,894,301 | $2,164,738,910 | |
| 5 | ALKS |
Alkermes plc.
|
29,235,739 | $1,531,952,715 | |
| 6 | VTRS |
Viatris Inc
|
86,019,468 | $1,365,989,144 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
48,849,973 | $1,202,197,829 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
28,703,514 | $995,150,823 |
All Filings in XERS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $115,042,262 | 14,525,539 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $75,085,548 | 12,945,785 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $99,218,640 | 12,639,318 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $97,091,464 | 11,927,699 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $53,874,614 | 11,536,321 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $59,262,355 | 10,794,601 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $36,683,619 | 10,821,128 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $30,591,985 | 10,734,031 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||